RU2017121002A - Ингибиторы CD38 и способы лечения - Google Patents
Ингибиторы CD38 и способы лечения Download PDFInfo
- Publication number
- RU2017121002A RU2017121002A RU2017121002A RU2017121002A RU2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A RU 2017121002 A RU2017121002 A RU 2017121002A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- compound
- compound according
- disease
- condition
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086844P | 2014-12-03 | 2014-12-03 | |
| US62/086,844 | 2014-12-03 | ||
| PCT/IB2015/058965 WO2016087975A1 (en) | 2014-12-03 | 2015-11-19 | Cd38 inhibitors and methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017121002A true RU2017121002A (ru) | 2019-01-11 |
| RU2017121002A3 RU2017121002A3 (enExample) | 2019-03-15 |
Family
ID=54708091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017121002A RU2017121002A (ru) | 2014-12-03 | 2015-11-19 | Ингибиторы CD38 и способы лечения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9840496B2 (enExample) |
| EP (1) | EP3227275B1 (enExample) |
| JP (1) | JP6550132B2 (enExample) |
| KR (1) | KR20170090478A (enExample) |
| CN (1) | CN107428733A (enExample) |
| AU (1) | AU2015356721B2 (enExample) |
| BR (1) | BR112017011642A2 (enExample) |
| CA (1) | CA2969178A1 (enExample) |
| ES (1) | ES2717260T3 (enExample) |
| RU (1) | RU2017121002A (enExample) |
| WO (1) | WO2016087975A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3544612A4 (en) | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
| BR112021012685A2 (pt) | 2019-01-11 | 2021-12-28 | Omeros Corp | Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica |
| CN119431323A (zh) * | 2019-07-31 | 2025-02-14 | 贝林格尔·英格海姆国际有限公司 | 作为cd38抑制剂的杂双环酰胺 |
| WO2021087087A1 (en) | 2019-10-30 | 2021-05-06 | Mitobridge Inc. | N-cyclohexyl-5-(thiazol-5-yl)-1h-indole-7-carboxamide derivatives and related compounds as cd38 inhibitors for increasing nad+ and for the treatment of e.g. muscular disorders |
| TW202204331A (zh) | 2020-04-07 | 2022-02-01 | 美商米突倍基公司 | Cd38抑制劑 |
| WO2022077034A1 (en) * | 2020-10-09 | 2022-04-14 | Napa Therapeutics Ltd. | Heteroaryl amide inhibitors of cd38 |
| PE20232047A1 (es) | 2021-01-29 | 2023-12-27 | Boehringer Ingelheim Int | Quinolinas y azaquinolinas como inhibidores de cd38 |
| JP2024517750A (ja) * | 2021-04-30 | 2024-04-23 | ナンキン イムノファージ バイオテック カンパニー リミテッド | 化合物及びそれらのｃｄ３８阻害剤としての使用 |
| JP2024525692A (ja) * | 2021-07-12 | 2024-07-12 | サイトキネティックス， インコーポレイテッド | Ｃｄ３８調節因子及びその使用方法 |
| WO2024254396A1 (en) * | 2023-06-07 | 2024-12-12 | Flagship Pioneering Innovations, Vi, Llc | Condensed azines as inhibitors of cyclic adp ribose hydrolase |
| CN119775288B (zh) * | 2024-12-31 | 2025-10-10 | 浙江工业大学 | 一种cd38抑制化合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2433840C (en) * | 2001-01-04 | 2010-05-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof |
| US7022680B2 (en) * | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| WO2010025235A1 (en) * | 2008-08-29 | 2010-03-04 | Regents Of The University Of Michigan | Selective ligands for the dopamine 3 (d3) receptor and methods of using the same |
| EP2801573A1 (en) * | 2013-05-09 | 2014-11-12 | Sanofi | Hydantoine derivatives as CD38 inhibitors |
-
2015
- 2015-11-19 US US15/529,120 patent/US9840496B2/en active Active
- 2015-11-19 WO PCT/IB2015/058965 patent/WO2016087975A1/en not_active Ceased
- 2015-11-19 BR BR112017011642A patent/BR112017011642A2/pt not_active Application Discontinuation
- 2015-11-19 RU RU2017121002A patent/RU2017121002A/ru not_active Application Discontinuation
- 2015-11-19 ES ES15801951T patent/ES2717260T3/es active Active
- 2015-11-19 CA CA2969178A patent/CA2969178A1/en not_active Abandoned
- 2015-11-19 JP JP2017529357A patent/JP6550132B2/ja active Active
- 2015-11-19 KR KR1020177018180A patent/KR20170090478A/ko not_active Withdrawn
- 2015-11-19 EP EP15801951.3A patent/EP3227275B1/en active Active
- 2015-11-19 AU AU2015356721A patent/AU2015356721B2/en not_active Ceased
- 2015-11-19 CN CN201580073761.2A patent/CN107428733A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016087975A1 (en) | 2016-06-09 |
| EP3227275B1 (en) | 2019-01-02 |
| EP3227275A1 (en) | 2017-10-11 |
| ES2717260T3 (es) | 2019-06-20 |
| US9840496B2 (en) | 2017-12-12 |
| CN107428733A (zh) | 2017-12-01 |
| US20170260164A1 (en) | 2017-09-14 |
| RU2017121002A3 (enExample) | 2019-03-15 |
| JP6550132B2 (ja) | 2019-07-24 |
| CA2969178A1 (en) | 2016-06-09 |
| JP2018501215A (ja) | 2018-01-18 |
| AU2015356721A1 (en) | 2017-06-08 |
| AU2015356721B2 (en) | 2018-03-15 |
| KR20170090478A (ko) | 2017-08-07 |
| BR112017011642A2 (pt) | 2018-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017121002A (ru) | Ингибиторы CD38 и способы лечения | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| JP2013523802A5 (enExample) | ||
| JP2018501215A5 (enExample) | ||
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| TN2017000204A1 (en) | Triazolopyrimidine compounds and uses thereof | |
| EA033061B1 (ru) | Спироциклогептаны как ингибиторы rock | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201691629A1 (ru) | Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения | |
| MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| WO2016085939A3 (en) | Compounds and methods of treating ocular disorders | |
| RU2016150410A (ru) | Ингибиторы фактора xia | |
| JP2015532645A5 (enExample) | ||
| EA201691150A1 (ru) | Соединения изопропилтриазолопиридина | |
| PH12017501598B1 (en) | Ã-D-2`-DEOXY-2`a-FLUORO-2`-Ã-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| MX382171B (es) | Inhibidores de replicacion del virus de influenza. | |
| EA201790343A1 (ru) | Способ получения сульфамидных производных пиримидина | |
| JP2017517512A5 (enExample) | ||
| EA201790337A1 (ru) | Кристаллические формы ингибиторов глутаминазы | |
| RU2018113718A (ru) | Новые соединения | |
| EA201690879A1 (ru) | Новое триазолопиридиновое соединение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190701 |